PUBLISHER: Grand View Research | PRODUCT CODE: 1224602
PUBLISHER: Grand View Research | PRODUCT CODE: 1224602
The global clinical trials management system market size is anticipated to reach USD 4.72 billion by 2030, expanding at a CAGR of 14.3% from 2023 to 2030, according to a new report by Grand View Research, Inc. The key factors driving the market growth include the rising number of clinical trials, digitalization across healthcare R&D, the growing number of decentralized trials, and product enhancements. The Clinical Trial Management System (CTMS) offered by SimpleTrials, for instance, includes features such as contact management, calendar & monitoring, project planning, document management & eTMF, contract & payment system, subject tracking, visit report authoring & letter generation, EDC integration, and reporting and business analytics.
The COVID-19 pandemic resulted in several challenges in conducting and operating clinical trials. As per a survey published by Oracle in 2021, 12% of respondents reported that clinical trial activity was paused. These respondents represented professionals involved in clinical trials at CROs, medical device companies, and biopharmaceutical companies. However, the urgency to develop vaccines and other treatment options supported the adoption of emerging technologies. These included video visits, phone visits, remote monitoring, eConsent, and EHR. In fact, about 76% of respondents reported that the pandemic catalyzed their adoption of decentralized clinical trial methods. The trend is projected to continue post-COVID and is expected to propel the demand for CTMS solutions.
Increasing investments by pharmaceutical and biotechnology companies, medical device companies, and CROs, coupled with government funding, are promoting research activities. This factor is expected to boost demand for clinical trial management systems. According to The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the global research-based biopharmaceutical industry has spent around USD 179 billion on R&D in 2018. This number was estimated to reach USD 202 billion by 2022. These investments facilitate the development of new medicines and vaccines to prevent and treat diseases. Some of the popular therapeutic areas for drug development include cancer, immunology, neurology, infectious diseases, and others.